º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Manufacturing

Support stood down for Smith & Nephew's ventilator venture as challenge selections made

OxVent well down the list after consideration by regulator and expert panel of clinicians

Smith & Nephew, and the OxVent prototype that has not been backed by government to progress.

The team behind the OxVent ventilator - which had been due to be built in Hull - has told how it stands ready to deliver,  if required, after government support ended.

A month ago the venture, from scientists, clinicians and medical technology manufacturers from the University of Oxford, King’s College London and Smith & Nephew, brought forward a solution to a desperate plea from Westminster.

It was at a time when Nightingale field hospitals were being readied, with devices desperately sought to ensure potential worst-case scenarios could be catered for.

Now - due to actual clinical need and reviews of those put forward - activity to supply the OxVent ventilator in the º£½ÇÊÓÆµ is to be stopped. The government has selected an initial two models - one newly adapted, one existing - with two further existing products to be scaled up and two under review. A further five others are on a reserve list.

The OxVent is one of four where government support has been pulled.

The team said that “that fewer ventilators are needed to treat º£½ÇÊÓÆµ patients is good news,” adding it remained in position to assist.

Smith & Nephew's Hull plant.

Developed to be produced at speed and scale and with a claim that it was at significantly lower cost than alternatives, it was conceived as an open source not-for profit project.

Professor Mark Thompson of Oxford University, said: “Every member of this outstanding team of engineers, medics and manufacturers has shown determination and drive, overcoming challenges while working at speed with ingenuity and focus. Responding to the Covid-19 crisis, using our talents and resources to the full, is a personal mission for all of us, and we are committed to sharing the resource we have developed with other countries where there is an urgent clinical need.”